Ripley E - Search Results

1

Pharmacokinetics of sematilide in renal failure.

Shi J, Ripley E, Gehr TW, Sica DA, Dandekar KA, Hinderling PH. Shi J, et al. Among authors: ripley e. J Clin Pharmacol. 1996 Feb;36(2):131-43. doi: 10.1002/j.1552-4604.1996.tb04178.x. J Clin Pharmacol. 1996. PMID: 8852389 Clinical Trial.

2

The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone.

Ripley EB, Gehr TW, Wallace H, Wade J, Kish C, Sica DA. Ripley EB, et al. Int J Clin Pharmacol Ther. 1994 Jan;32(1):12-8. Int J Clin Pharmacol Ther. 1994. PMID: 8199745

3

Simple method for determination of hydrochlorothiazide in human urine by high performance liquid chromatography utilizing narrowbore chromatography.

Farthing D, Fakhry I, Ripley EB, Sica D. Farthing D, et al. Among authors: ripley eb. J Pharm Biomed Anal. 1998 Sep;17(8):1455-9. doi: 10.1016/s0731-7085(98)00021-1. J Pharm Biomed Anal. 1998. PMID: 9800665

4

Hormonal, blood pressure, and peritoneal transport response to short-term ACE inhibition.

Ripley EB, Gehr TW, Kish CW, Sica DA. Ripley EB, et al. Perit Dial Int. 1994;14(4):378-83. Perit Dial Int. 1994. PMID: 7827189 Clinical Trial.

5

Racial differences in response to acute dosing with hydrochlorothiazide.

Ripley E, King K, Sica DA. Ripley E, et al. Am J Hypertens. 2000 Feb;13(2):157-64. doi: 10.1016/s0895-7061(99)00168-5. Am J Hypertens. 2000. PMID: 10701815

6

Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators.

Oparil S, Levine JH, Zuschke CA, Gradman AH, Ripley E, Jones DW, Hardison JD, Cushing DJ, Prasad R, Michelson EL. Oparil S, et al. Among authors: ripley e. Am J Cardiol. 1999 Aug 1;84(3):289-93. doi: 10.1016/s0002-9149(99)00278-7. Am J Cardiol. 1999. PMID: 10496437 Clinical Trial.

7

Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney disease.

Ripley E. Ripley E. Am Heart J. 2009 Jun;157(6 Suppl):S7-S16. doi: 10.1016/j.ahj.2009.04.008. Am Heart J. 2009. PMID: 19450722 Review.

8

Darbepoetin alfa therapeutic interchange protocol for anemia in dialysis.

Brophy DF, Ripley EB, Kockler DR, Lee S, Proeschel LA. Brophy DF, et al. Ann Pharmacother. 2005 Nov;39(11):1808-11. doi: 10.1345/aph.1G329. Epub 2005 Sep 27. Ann Pharmacother. 2005. PMID: 16189281

9

Paying Clinical Research Participants: One Institution's Research Ethics Committees' Perspective.

Ripley EB, Macrina FL, Markowitz M. Ripley EB, et al. J Empir Res Hum Res Ethics. 2006 Dec;1(4):37-44. doi: 10.1525/jer.2006.1.4.37. J Empir Res Hum Res Ethics. 2006. PMID: 19385836

10

Pharmacoeconomic considerations in the health system management of anaemia in patients with chronic kidney disease and end stage renal disease.

Brophy DF, Ripley EB, Holdford DA. Brophy DF, et al. Expert Opin Pharmacother. 2003 Sep;4(9):1461-9. doi: 10.1517/14656566.4.9.1461. Expert Opin Pharmacother. 2003. PMID: 12943475 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29 results

Search Page

Filters